

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 June 2022 (30.06.2022)



(10) International Publication Number
WO 2022/136642 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) *C07K 16/30* (2006.01)

A61P 35/00 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2021/087495

(22) International Filing Date:

23 December 2021 (23.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20 216 800.1 23 December 2020 (23.12.2020) EP

(71) Applicant: **SOTIO BIOTECH A.S.** [CZ/CZ]; Jankovcova 1518/2, 170 00 Prague 7 (CZ).

(72) Inventors: **BAMMERT, Lukas**; Martinsgasse 18, 4051 Basel (CH). **KYRYCH SADLIKOVA, Lenka**; Velvarska 991, 25262 Horomerice (CZ). **HOSKOVA, Simona**; Pelechovska 1, 19017 Prague 9 (CZ). **VALENTOVA, Ina**; Druzstevni 207, 37367 Ceske Budejovice (CZ). **WALDMEIER, Lorenz**; Peter-Rot-Strasse 66, 4058 Basel (CH). **BEERLI, Roger**; Rebrainstrasse 34, 8106 Adlikon bei Regensdorf (CH). **MOEBIUS, Ulrich**; Am Rain 7, 82131 Gauting (DE).

(74) Agent: **MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH**; Dr. Dirk Bühler, Elisenhof, Elisenstrasse 3, 80065 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATES

(57) Abstract: The invention provides an ADC based on an antibody binding to CLDN18.2, wherein the antibody or fragment thereof exhibits increased binding to tumor tissue expressing CLDN18.2 over healthy tissue expressing CLDN18.2.

WO 2022/136642 A1